

SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS- ESTABLISHING A EUROPEAN PICO

Schreuder, C, Willemsen, A.
Zorginstituut Nederland, Diemen, Netherlands

Objectives & Methods

To prepare the European landscape on the future of joint HTA work, EUnetHTA continuously refines its procedures. One of these changes is the implementation of the PICO survey.

- Piloted as of the fourth pharmaceutical Joint Clinical Assessment (JCA)
- Serve to **establish a European PICO** for the JCA to facilitate national implementation
- EUnetHTA analysed the experiences of establishing a European PICO of all finalized PICO surveys

The PICO survey is published online in the early stage of the scoping phase, allowing EUnetHTA Pharma Partners to agree with or comment on the proposed patient population, indication, comparators and outcomes (PICO) for the upcoming JCA.

Results

As of 07/2018, the PICO survey has been used for ten JCAs.

- The first four PICO surveys were based on the PICO proposed by the manufacturer and the last six PICO surveys considered a **PICO as proposed by the authoring team** of the JCA.
- For four PICO surveys a single European PICO was proposed. For the other six surveys two PICOs were proposed.

Difference PICO 1 vs PICO 2




Figure 1: Difference in PICO elements when multiple PICOs were proposed

Level of agreement on PICO elements




Figure 2: Level of agreement on different PICO elements per pharma JCA (PTJA)
* For PTJA10, PTJA12 and PTJA 13 the PICO survey is ongoing

On average, 11 of the 28 countries (39%) responded to the survey, 14 countries (50%) were involved in the development of the EUnetHTA PICO when also considering the assessment team members (including the three ongoing surveys).

Conclusions

- PICO survey welcomed by many EUnetHTA partners
- European PICO for JCA **more transparent**
 - The PICO survey will be used for all future JCAs
- Challenges:
 - Non-response when topic not of relevance?
 - When to **include national suggestions** in the European PICO?
 - How many countries need to request additional data before it is of European relevance?

Contact

For an overview of all products under assessment or compounds prioritized by EUnetHTA , please visit:
www.eunetha.eu/REA

For further information on the procedure, please contact us on:
WP4_Pharmaceuticals@zinl.nl

"Disclaimer" The contents of this poster arise from the EUnetHTA JA3 which has received funding from the EU, in the framework of the Health Programme. Sole responsibility for its contents lies with the author(s) and neither the EUnetHTA Coordinator nor the Executive Agency for Health and Consumers is responsible for any use that maybe made of the information contained therein.